Abstracts tagged "Interleukins"

Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Janet Pope¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Serge Perrot⁴, Yvonne Lee⁵, Anthony Sebba⁶ and Ernest Choy⁷, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Paris Descartes University, Paris, Ile-de-France, France, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Arthritis Associates, Palm Harbor, Tampa, FL, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
Abstract Number: 1224 • ACR Convergence 2020
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Esteban Rubio Romero¹, Alejandro Muñoz Jiménez², Rosalia Martinez Perez³ and Lara Mendez Diaz⁴, ¹VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, ²H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ³Virgen del Rocío University Hospital, seville, Spain, ⁴Virgen del Rocío Hospital, sevilla, Spain
Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
Abstract Number: 1632 • ACR Convergence 2020
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Joerg Henes¹, Norbert Blank², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Markus Hufnagel⁶, Tilmann Kallinich⁷, Birgit Kortus-Goetze⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, ⁷Charite, Berlin, Germany, ⁸Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully treated with the anti-IL-1ß inhibitor canakinumab.…
Abstract Number: 0068 • ACR Convergence 2020
Single Cell RNA-seq to Characterize Monocyte Subtypes in the Autoinflammatory Interferonopathy, SAVI and the Inflammasomopathy, NOMID
Ying Zhang¹, Bernadette Marrero², Adriana de Jesus³, Sara Alehashemi⁴, Jinguo Chen⁵, Rongye Shi⁶, Huizhi Zhou⁶, Clifton Dalgard⁷, Manfred Boehm⁸ and Raphaela Goldbach-Mansky⁹, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, ³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, ⁵Molecular Immunology Section, National Eye Institute, National Institutes of Health, Bethesda, MD, ⁶Molecular Immunology Section, National Eye Institute, National Institutes of Health, Bethesda, ⁷Department of Anatomy, Physiology and Genetics, Uniformed Services University of Health Sciences, Bethesda, ⁸Center for Molecular Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Monocytes are pivotal producers of key inflammatory cytokines that drive autoinflammatory diseases. In SAVI, constitutive STING activation causes chronic activation with increased type-I IFN…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 1225 • ACR Convergence 2020
Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy
Yoshinobu Koyama¹, Yoshiharu Sato², Hiroshi Iijima², Moe Sakamoto³ and Toshie Higuchi³, ¹Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Division of Rheumatology, Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan
Background/Purpose: Inhibition of IL-6 signaling is one of the most established strategies for RA treatment. Tocilizumab (TCZ) is the pioneer which blocks IL-6 signaling by…
Abstract Number: 1824 • ACR Convergence 2020
Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358
Christie Fanton¹, Richard Furie², Neha Dixit¹, Cat Haglund¹, Lin Lu¹, Suresh Siddhanti¹, Vishala Chindalore³, Robert Levin⁴, Isam Diab⁵, Brian Kotzin¹ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Division of Rheumatology, Northwell Health, Great Neck, NY, ³Pinnacle Research Group, Anniston, AL, ⁴Clinical Research of West Florida, Clearwater, FL, ⁵Paramount Medical Research and Consulting, Middleburg Heights, OH
Background/Purpose: Treg dysfunction and impaired IL-2 production have been implicated as key immunological defects in the breakdown of immune self-tolerance in SLE. Low-dose IL-2 can…
Abstract Number: 0099 • ACR Convergence 2020
Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis
Aleksandra Bukina¹ and Anna Mihailova¹, ¹Rigas Stradins university, Riga, Latvia
Background/Purpose: Persistent synovitis without known markers such as rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) as well as without genetic markers as HLAB27 is not…
Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Andrea Rubbert Roth¹, Daniel Furst*², Stefano Fiore³, Amy Praestgaard⁴, Vivian Bykerk⁵, Clifton Bingham III⁶ and Christina Charles-Schoeman⁷, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
Abstract Number: 1911 • ACR Convergence 2020
IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1
Caya McFalls¹ and Carol Artlett¹, ¹Drexel University College of Medicine, Philadelphia
Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…
Abstract Number: 0173 • ACR Convergence 2020
mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice
Zhengping Huang¹, Ying Li², Alexandra Wactor³, Peter Nigrovic⁴ and Pui Lee⁵, ¹1.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, ²1.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁵1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…
Abstract Number: 0834 • ACR Convergence 2020
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Stefano Fiore¹, Lang Chen², Cassie Clinton², Huifeng Yun², Amy Praestgaard³, Kerri Ford³ and Jeffrey R Curtis², ¹Sanofi, Bridgewater, NJ, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Sanofi, Cambridge, MA
Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
Abstract Number: 1234 • ACR Convergence 2020
Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab
Ernest Choy¹, Vivian Bykerk², Yvonne Lee³, Gregory St John⁴, Hubert van Hoogstraten⁵, Kerri Ford⁶, Amy Praestgaard⁶ and Anthony Sebba⁷, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Sanofi, Cambridge, MA, ⁷Arthritis Associates, Palm Harbor, Tampa, FL
Background/Purpose: Inflammation is a key driver of pain in rheumatoid arthritis (RA). However, in some patients the level of pain exceeds what would be expected…
Abstract Number: 1920 • ACR Convergence 2020
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
Andrea Rubbert Roth¹, Scott Tschuppert², Thomas Neumann², Ulf Benecke³, Ian Pirker³ and Johannes von Kempis³, ¹Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ²Kantonsspital St Gallen, St.Gallen, Switzerland, ³Kantonspital St Gallen, St. Gallen, Switzerland
Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].